GlaxoSmithKline Pharmaceuticals to transfer rights of Iodex and Ostocalcium brands to GSK Asia

27 Jul 2021 Evaluate

GlaxoSmithKline Pharmaceuticals has decided to transfer its rights in relation to the Iodex and Ostocalcium brands to GlaxoSmithKline Asia, for an aggregate consideration of Rs 1649 crore. The transaction is expected to be completed before the end of the year, subject to shareholder approval and the customary closing conditions, including relevant regulatory approvals.

GlaxoSmithKline Pharmaceuticals is an Indian subsidiary of GlaxoSmithKline plc. The company business has a broad portfolio of innovative and established medicines, with leadership positions in respiratory and HIV. 

Glaxosmithkline Phar Share Price

2454.60 -16.35 (-0.66%)
01-Jan-2026 10:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1713.60
Dr. Reddys Lab 1255.15
Cipla 1504.35
Zydus Lifesciences 909.90
Lupin 2086.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×